ATS 2024 Final Program

Click on the session title to view the speakers

243

TUESDAY • MAY 21

Manifestations and Long-term Corticosteroid Benefit: An Analysis of Allergy Practices in the United States P636 The Effect of Benralizumab Versus Mepolizumab on the Depletion of Eosinophils in the Treatment of Eosinophilic Granulomatosis With Polyangiitis During the Phase 3 MANDARA Study P637 Blood Eosinophil Phenotype During Treatment With Mepolizumab in Patients With Severe Eosinophilic Asthma P638 Impact of Disease, Use of Biologics and Clinical Remission in Severe Asthma: Insights From a Multicenter Longitudinal Real-life Registry in Brazil P639 Dupilumab Reduces Severe Exacerbations and Improves Lung Function in Patients With Type 2 Asthma Irrespective of Asthma Duration P640 Dupilumab Add-on to Medium-dose Inhaled Corticosteroid (ICS) Increases Odds of Asthma Control and Reduces FeNO Compared With Placebo Add-on to High-dose ICS P641 Liberal Withdrawal From Oral Corticosteroids Maintenance Therapy After Introduction of a Biological Agent Targeting Type 2 Inflammation in Severe Asthma P642 Use of Biologics and Asthma Remission in Underrepresented Patient Populations P643 Efficacy of Tezepelumab in Black or African American Patients: A Pooled Analysis of The PATHWAY and NAVIGATOR Studies P644 Dependence on a Single Blood Eosinophil Count May Lead to Misdiagnosis of Eosinophilic Asthma Phenotype and Misuse of Biologics in an Urban Cohort P645 Impact of Adherence to Maintenance Therapy, as Measured Using Digital Inhaler Data, on Asthma Control and Healthcare Resource Utilization Among Patients Using Biologics P646 A Phase 4, Single-arm, Open-label Study to Evaluate the Effectiveness and Safety of Tezepelumab in Patients With Severe Asthma, Including Underrepresented Racial and Clinical Groups: Initial Baseline Demographics and Clinical Characteristics From the PASS

P647 Effect of Tezepelumab on Exercise Tolerance in Patients With Severe, Uncontrolled Asthma From the NAVIGATOR Study P648 Impact of Atopic Status, Prior Omalizumab Use and Baseline Blood Eosinophil Count Alone and in Combination With Total Serum IgE on Maintenance OCS Reduction Outcomes in Patients With Severe Asthma Treated With Mepolizumab in the REALITI-A Study P649 Safety Profile of Astegolimab, An Anti-ST2 Antibody: A Systematic Review P650 Dupilumab Superior to Other Asthma Biologics to Treat Allergic Bronchopulmonary Aspergillosis in a Retrospective Study P651 Efficacy of Biologics for Reducing Exacerbations Requiring Hospitalization or an Emergency Department Visit in Patients With Moderate-to-Severe, Uncontrolled Asthma P652 Long-term Effects of Biological Agents on Respiratory Function P653 Mepolizumab to Benralizumab: A Case Series of a Beneficial Switch in Severe Asthma P654 Real-world Experience With Tezepelumab for Severe Asthma in an Academic Medical Center P655 Systematic Literature Review of Real-world Outcomes of Benralizumab in Eosinophilic Granulomatosis With Polyangiitis P656 SWIFT-1 and SWIFT-2 Study Design: Replicate Phase 3A Randomized, Double-blind, Placebo-controlled, Multicenter Studies of the Efficacy and Safety of Depemokimab in Patients With Asthma With an Eosinophilic Phenotype P657 APG808, A Fully Human Monoclonal IgG1 Antibody, Binds to IL-4R a With High Affinity and Blocks IL-13 and IL-4 Mediated Signalling in Multiple In Vitro Assays P658 FeNO and Blood Eosinophils as Potential Predictive Biomarkers for Effectiveness of Dupilumab in Real-life Severe Asthma: Japanese Multi-center Prospective Cohort P659 Simultaneous Blockade of IL-4 and IL-13 Signaling With Dupilumab Attenuates Type 2 Inflammation and Airway Remodeling in a Mouse Model of Severe Airway Disease

ATS 2024 Conference Program • San Diego, CA